Currency in GBP
Last close As at 26/05/2023
GBP0.38
▲ −1.00 (−2.56%)
Market capitalisation
GBP91m
Research: Investment Companies
In our last update on Seraphim Space Investment Trust (SSIT), published in October 2022 (Weathering the storm), we reviewed the company’s inaugural full year results and in this update we focus on its Q123 NAV performance. SSIT’s manager (Seraphim Space Manager LLP) is keen to draw attention to the valuation methodology and deal structure for the nine unquoted holdings in the portfolio’s top 10 holdings. These account for c 85% of the current value of all private holdings in the fund and 77% of the overall invested portfolio value at the end of September, highlighting how the structure of an investment is a crucial determinant of performance, especially in a weaker investment environment, and supportive of NAV. Seraphim has modelled the valuation sensitivity of these nine private holdings, testing a theoretical 50% reduction in enterprise value to each holding and gauging the notional impairment to SSIT’s NAV. Seraphim is not forecasting this reduction, but even if it were to occur it calculates that the NAV could still be c 85p or only c 19% below the Q123 NAV of 105p.
Seraphim Space Investment Trust |
The importance of deal structure in weak markets |
Investment trusts |
16 December 2022 |
Analysts
|
In our last update on Seraphim Space Investment Trust (SSIT), published in October 2022 (Weathering the storm), we reviewed the company’s inaugural full year results and in this update we focus on its Q123 NAV performance. SSIT’s manager (Seraphim Space Manager LLP) is keen to draw attention to the valuation methodology and deal structure for the nine unquoted holdings in the portfolio’s top 10 holdings. These account for c 85% of the current value of all private holdings in the fund and 77% of the overall invested portfolio value at the end of September, highlighting how the structure of an investment is a crucial determinant of performance, especially in a weaker investment environment, and supportive of NAV. Seraphim has modelled the valuation sensitivity of these nine private holdings, testing a theoretical 50% reduction in enterprise value to each holding and gauging the notional impairment to SSIT’s NAV. Seraphim is not forecasting this reduction, but even if it were to occur it calculates that the NAV could still be c 85p or only c 19% below the Q123 NAV of 105p.
Q1 NAV results presentation |
|
Source: Seraphim Space Investment Trust |
Why consider SSIT now?
There is no denying that 2022 has been a very difficult period for early-stage growth investors. Surging inflation and rising interest rates have removed a substantial leg of valuation support for long-duration growth assets. In this environment there may be some investor concern regarding the apparent disconnect between what has happened to the valuations of some early-stage growth assets in the public markets and the less frequent NAVs published by largely private-focused investment vehicles such as SSIT. In order to address these concerns, the management of SSIT has set out its valuation methodology, the structure of the deals and modelled a majority of the private holdings’ value in the event of a 50% decline in their enterprise values, which highlights the resilience of the NAV.
Q123 NAV performance
SSIT’s Q123 (to 30 September 2022) NAV was 1.05p, up from 99.97p at the 30 June 2022 financial year end. The value of the portfolio increased by 11% from £186.1m at 30 June 2022 to £207.0m at 30 September 2022. The fair value of investments was written down by £1.7m, with £8.8m added to existing and new investments. The largest single contributor to the increase in the value of the portfolio was £13.8m driven by the weakness of sterling over the period. At the end of September 2022 there were cash reserves of £44m (30 June 2022: £57m) or 18% of NAV, which, according to the company, is sufficient to support and adequately capitalise portfolio companies into 2024. The manager is maintaining its conservative approach to investment with less than £10m being deployed in each of the last three quarters. In total SSIT had net assets of £250m at the end of September 2022 (30 June 2022: £239m).
Investment activity in Q123
The rate of investment in the quarter was similar to previous quarters, with seven investments made overall during the period, with initiations in Voyager Space Holdings (a B series funding round, with a £2.1m investment), Taranis (a D series funding round, with £2.1m invested) and a modest new position acquired in a seed portfolio company (£0.3m).
Voyager builds next-generation space stations and has been commissioned by NASA in this regard. Its work is critical as the International Space Station reaches the end of its operational life. Voyager’s Starlab platform could be a solution to hosting both private and public astronauts. Voyager’s key functionality in developing non-earth-based R&D in biopharma has ground-breaking implications for manufacturing in space.
Taranis is an agriculture analytics business that can capture, utilising drones and space observation, sub centimetre level data and subsequently analyse the readings to help early identification of crop diseases, pestilence or crop failures due to lack of water or nutrients. It principally sells its findings to agriculture product retailers, with the ultimate aim of helping farmers maximise their yields, reducing waste and loss.
In addition, there were four follow-on investments including Planet Watchers (£2.5m) and three seed portfolio companies (£1.9m in total).
The anomalies between private and public markets
The Q123 NAV of 1.05p equated to a 5% uplift on the June year end figure of 99.97p and leaves the portfolio flat in terms of NAV over 2022. Despite this, the shares currently trade around 45p, which is a c 56% discount to the Q123 NAV.
Exhibit 1: SSIT’s discount mirrors that of its AIC peers |
Exhibit 2: SSIT’s NAV has held up better than peers |
Source: Morningstar. Note: AIC peer group returns = simple average. |
Source: Morningstar. Note: AIC peer group returns = simple average. |
Exhibit 1: SSIT’s discount mirrors that of its AIC peers |
Source: Morningstar. Note: AIC peer group returns = simple average. |
Exhibit 2: SSIT’s NAV has held up better than peers |
Source: Morningstar. Note: AIC peer group returns = simple average. |
In the year to date, quoted global markets, especially those in long-duration growth assets, have sold off aggressively and there appears to be a disconnect between the valuation attributed to the SSIT unlisted portfolio and what is happening in the quoted markets. While this is not unique to SSIT, investors have been unwilling to trust the NAV performance, instead ‘voting with their feet’ and leaving this and other private focused trusts on wide discounts to their stated NAVs. Exhibits 1 and 2 illustrate the respective discounts and NAV performance over 2022 to date for SSIT and its AIC Growth Capital peer group, while Exhibits 3 and 4 illustrate the price performances of a range of comparators and of the three listed holdings within the SSIT portfolio.
Exhibit 3: Share price performances of SSIT and comparators through 2022 |
Exhibit 4: Quoted holdings performances through 2022 |
Source: Morningstar. Note: AIC peer group returns = simple average. In pounds sterling. |
Source: Morningstar. Note: In pounds sterling. |
Exhibit 3: Share price performances of SSIT and comparators through 2022 |
Source: Morningstar. Note: AIC peer group returns = simple average. In pounds sterling. |
Exhibit 4: Quoted holdings performances through 2022 |
Source: Morningstar. Note: In pounds sterling. |
The structuring of an investment is key
In the manager’s latest update, it explained more about the structure of the holdings within the portfolio, revealing downside protection measures that are routine across the private companies within the portfolio via preference shares, rather than common equity or convertible loan notes. Preference shares sit above common equity in the capital structure in the event of a liquidity event, but below some other creditors such as banks. Preference shares offer more defensive exposure to an asset with their ‘liquidation preference’. Liquidation preferences provide a prioritised return ahead of other share classes, which means value can be preserved even in scenarios where a business is sold at a far lower valuation than that used to make the investment.
Another feature employed by the managers are ‘anti-dilution’ measures that retrospectively amend the price paid or the number of shares owned where a subsequent funding round is done at a lower valuation (down round). These measures can help mitigate dilution in the event of a down round, but it rarely results in no dilution. Additional shares are often issued at par to ensure that existing investors are not diluted in the event of a down round, protecting their investment and call on the company’s assets and cash flows. Anti-dilution can be full ratchet (100% price adjustment, ie the share price of the original investment is re-based to match the share price of the down round) or weighted average dilution, which provides a proportion of adjustment and less protection, but still a better outcome than if no anti-dilution measures were applied in the event of a down round.
All the top 10 private companies in the portfolio are structured via preference shares and feature liquidation preference with weighted average anti-dilution protection. Four of the holdings (ICEYE, HawkEye 360, Altitude Angel and Astroscale), which account for 36% of NAV, rank in the top tier of the company’s equity structure, and the remaining top 10 positions vary from 93% of the holding ranked in the top tier (All Space) to 0% (D-Orbit). In aggregate across the top 10 private companies there are quite substantial margins or buffers in place for the current enterprise values used to price the holdings. These margins would require significant derating in order for the holdings to be worth less than cost. Seraphim calculates that on an average NAV weighted basis the margin until loss is 53%, while the mean valuation margin is 62%. This implies that the enterprise values of these holdings in aggregate would have to fall in value by over half to impair their cost value.
Private companies’ NAV resilience
In order to address investor scepticism around the Q123 NAV and the wide discount at which SSIT shares currently trade to this, Seraphim has modelled the top 10 private holdings at 30 September 2022 (which accounted for 77% of overall portfolio value) and applied a range of enterprise value impairments to these holdings. If the enterprise value of each of these holdings fell by 50% from the Q123 valuation (via an event such as a funding round, IPO or trade sale etc) then the NAV per share would reduce from the current 105p to c 85p (or a c 19% decline), which compares to the current price of 45.7p, which is a 46% discount to this worst-case theoretical NAV. The current discount to SSIT’s Q123 105p NAV is 56.5%. The modelled resilience of the NAV is due to the liquidation preference and anti-dilution measures in place as explained above, which protects the value of these investments even in the event of quite dramatic falls in the enterprise value of the holdings. Seraphim is keen to state that it views a 50% decline in the enterprise values of these holdings as extremely unlikely given their operational performance, but if it did happen then SSIT’s NAV should have an element of downside protection.
NAV methodology recap
SSIT’s current NAV (at £1.05 per share) is £250.3m with a market cap of £109.5m, which is a discount of 56%. A market cap of £109.5m equates to 45p per share. There is also £43.8m of cash held by the company (equating to 18.3p per share) so the implied portfolio value (if cash is valued at nothing) is £65.7m, which is a 68% discount to the current NAV (less cash) of £206.5m.
An unaudited NAV is calculated quarterly in pounds sterling for end September, December, March and June. The June NAV is independently audited by BDO, which tested 99% of the total investment valuation. Publicly listed securities are valued at their bid price or last traded price (these currently comprise Arqit (ARQQ), Spire (SPIR) and AST SpaceMobile (ASTS)). However, the majority of the portfolio is unquoted. These assets are valued using International Private Equity and Venture Capital Association (IPEV) methodology including earnings multiples, discounted cash flow analysis or the use of the value at the most recent funding round. More recent purchases may be held at cost until such time that alternative measures become more appropriate. Assets yet to generate profit or revenue are typically valued at the most recent funding round cost. The above factors, and the nature of the portfolio, containing early-stage and unquoted assets, mean that there is likely to be an inherent element of lag in the quarterly reported NAV.
At the 2022 financial year end (30 June) 9.9% of the portfolio was valued via the available market price, which are the listed holdings of Arqit, Spire and AST SpaceMobile, and 11.3% via milestone multiples, with the majority of the portfolio valued in relation to funding rounds between three and six months ago (30.1%) and those where funding rounds occurred over six months ago (35.1%).
Often there will be only one ‘event’ per year from which to value an unlisted holding such as via a fund-raising, sale or listing. This means that often there is a subjective element to the valuation process (albeit within clearly stated IPEV parameters). In some ways there is a similarity between valuing the early-stage growth businesses within SSIT and biotech, in that the achievement of early-stage milestones are a catalyst for a re-rating, although until these companies fully prove their operational, technological and commercial development then the valuation may be considered transitory. Seraphim is well placed to verify the valuations of the unquoted companies as it tracks public and private industry transactions through its quarterly published space index, has recourse to proprietary databases and also uses third-party information providers such as Pitchbook.
The performance of special purpose acquisition companies (SPACs) through 2022 has been weak as investors have shunned early-stage growth investments. SSIT owns three listed companies (Arqit Quantum, Spire Global and AST SpaceMobile). With the exception of AST SpaceMobile, the share price performances of these holdings has been weak in 2022, with some listed early-stage companies affected by a lack of liquidity or by short sellers. Spire Global and Arqit Quantum are within SPAC structures and have seen their share prices sell off materially in 2022, while AST SpaceMobile, which is also listed via a SPAC, has been more resilient through 2022. Seraphim does not believe that there is ‘read across’ from the performances of Spire Global and Arqit Quantum to the unquoted portfolio. Instead, it points to the performances of the Nasdaq and sector indices (Exhibit 3) as more relevant proxies.
Conclusion
It is business as usual for SSIT in many regards in that the portfolio is very much geared to address the vast issues confronting the planet now and in the future. We covered these in our August 2022 review (Derating offers an attractive entry point), highlighting the 90% of earnings from the top 10 private portfolio holdings directly derived from climate change and global security themes. These are themes that are likely to be supportive of very long-term secular growth in these end markets. This focus together with the downside protection measures in place provides a powerful following wind for the portfolio and a degree a downside protection. Investors will be interested to see Seraphim’s latest modelling, in which it has applied a 50% decline to the enterprise values of the top 10 private companies, which if were to come to fruition would result in an NAV of c 85p. Given all of these factors, the c 56% discount to NAV could be considered excessive and unrepresentative of the portfolio’s operational performance and the vast end market potential demand that the portfolio addresses. Investor sentiment towards early-stage companies could remain fragile for some time yet, however for those investors with the appropriate appetite to risk and investment time horizon, SSIT may be attractive at these levels.
|
|
Investment Companies
Investment Companies
Research: Healthcare
Meeting its prior guidance, Pixium Vision has now completed all of the implantations required as part of the PRIMAvera pivotal trial assessing the safety and clinical benefits of the wireless Prima System in patients with geographic atrophy due to age-related macular degeneration (GA-AMD). In total, 38 patients have been implanted with the Prima sub-retinal photovoltaic device and Pixium expects to report primary endpoint data around the end of 2023, filing for European approval in H124. We continue to model for EU market approval in H125.
Get access to the very latest content matched to your personal investment style.